Transactivation of the estrogen receptor promoter by BRCA1 by William B. Archey & Bradley A. Arrick
Archey and Arrick  Cancer Cell Int  (2017) 17:33 
DOI 10.1186/s12935-017-0401-2
PRIMARY RESEARCH
Transactivation of the estrogen receptor 
promoter by BRCA1
William B. Archey1,2 and Bradley A. Arrick1,2* 
Abstract 
Background: Absence of the estrogen receptor-α (ER) is perhaps the most distinctive pathological feature of breast 
cancers arising in women who inherit a mutation in BRCA1. Two hypotheses, not necessarily mutually exclusive, exist 
in the literature that describe mechanisms of ER transcriptional repression in breast cancer. One hypothesis suggests 
that methylation of cytosine–guanine dinucleotides (CpGs) primarily mediates repression, while the other maintains 
that transcriptional control is mediated by certain positive and negative promoter elements.
Methods: To determine if wild type BRCA1 could induce activity of the ER promoter, we performed a series of tran-
sient transfections with ER promoter segments linked to a luciferase reporter. The effect of BRCA1 on endogenous ER 
expression was evaluated by RNA analysis.
Results: Following cotransfection with a BRCA1 expression plasmid, we observed that ER promoter-driven luciferase 
activity was significantly increased in both MCF10A and IMEC cells (p < 0.005 and 0.0005 respectively, two-tailed t 
test). Specifically, the full length ER promoter construct showed approximately 5.6-fold (MCF10A) and tenfold (IMEC) 
increases in luciferase activity following BRCA1 transfection, compared with transfection with an empty expression 
plasmid (i.e. lacking BRCA1 sequence). We localized the ER promoter segment responsible for transactivation by 
BRCA1 to a 109 bp region containing an AP2γ homologous site.
Conclusions: The work described here, along with previously published work, indicates that activity of certain tran-
scriptional regulatory elements and CpG methylation both represent important mechanisms by which the ER gene 
is typically inactive in breast cancers associated with BRCA1 mutations. The absence of ER in these breast cancers has 
significant implications for pathogenesis, prevention, and treatment.
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Background
One of the most distinctive biological features of breast 
cancers that arise in women who inherit an altered copy 
of the BRCA1 gene is a lack of expression of the ER [1–3]. 
The correlation between loss of BRCA1 and the ER-neg-
ative phenotype extends to sporadic (i.e. non-inherited) 
breast cancers as well [4–6]. Considering the importance 
of estrogen-based signaling in the genesis and progres-
sion of breast cancer, this characteristic of BRCA1-linked 
breast cancers has important consequences for the 
treatment and prevention of these cancers. We have 
therefore endeavored to elucidate the molecular basis 
of the ER-negative phenotype in breast cancers lacking 
BRCA1. Two non mutually exclusive mechanisms have 
been proposed to account for the lack of ER expression 
in some sporadic breast cancers, one epigenetic and the 
other transcriptional. Epigenetic silencing of ER expres-
sion by cytosine methylation within the CpG island 
associated with the 5′ region of the gene has been well 
documented in both cell lines and tumor tissue [7–9]. 
We have reported that CpG methylation of the ER gene 
is more extensive in ER-negative BRCA1-linked breast 
cancers compared with ER-negative breast cancers not 
linked to germline mutations in BRCA1 [10].
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Expression of the ER can also be regulated at the tran-
scriptional level, by the availability and activity of DNA-
binding proteins that interact with portions of the ER 
promoter in a sequence-specific manner. The upstream 
promoter region of the ER has been reported to mediate 
transcription initiation from two alternative promoters, 
a proximal promoter termed P1 and a distal promoter 
called P0, yielding similarly sized mRNA transcripts 
with slightly different 5′ untranslated regions but identi-
cal coding regions. Analysis of ER-positive breast cancer 
cell lines and primary tumors indicates that the P1 pro-
moter is the predominant site for initiation of transcrip-
tion, but that the upstream P0 promoter may be active as 
well in some settings [11, 12]. Five groups have charac-
terized distinct functional promoter elements, extend-
ing to ~4  kb upstream of P1. The most downstream of 
the elements, located within the 5′ noncoding region 
just upstream of the ATG start codon, is a positive ele-
ment termed ERF-1 that binds the transcription factor 
AP2γ [13, 14]. Midway between P1 and P0 is another 
positive regulatory element, termed ERUBF-1, that func-
tions as a transcriptional enhancer element in MCF-7 
cells [15]. Hayashi et  al. [12] have provided the clearest 
evidence that the upstream P0 promoter is also utilized 
in ER-positive breast cancers. They have described a 
transcriptional enhancer element in close proximity to 
this promoter that significantly augments transcription 
from P0-based promoter constructs in MCF-7 cells [16]. 
Furthermore, ER-positive cell lines that utilize P0 were 
shown to contain nuclear factors that specifically bind to 
this sequence, termed ERBF-1. A negative cis element, 
located ~3.2 kb upstream of P1, was identified via a strat-
egy of transfecting cells with decoy fragments of dsDNA 
corresponding to segments of promoter sequence. Using 
this approach, Penolazzi et  al. [17] reported that intro-
duction of multiple copies of decoy dsDNA correspond-
ing to a putative 102 bp negative element into MCF-7 or 
MDA-231 cells increased or reactivated ER expression, 
respectively. By RT-PCR, they showed that ER mRNA 
transcripts corresponding to the P0 promoter were the 
predominantly induced species, with undetectable lev-
els of P1-derived ER mRNA. Finally, the most upstream 
positive enhancer element, termed ER-EH0 was mapped 
to a 35  bp segment beginning at −3744, relative to P1. 
Multiple DNA–protein complexes were demonstrated 
with this sequence, one of which included AP-1 [18]. The 
positions of these five regulatory elements, relative to the 
transcription start sites, are illustrated in Fig. 1.
We investigated transactivation of the ER promoter 
region by BRCA1 in two nontumorigenic mammary epi-
thelial cell lines, MCF10A and IMEC. A series of ER pro-
moter constructs were prepared and cotransfected with a 
BRCA1 expression plasmid. Here, we report that BRCA1 
is able to transactivate the ER promoter in both MCF10A 
and IMEC cells and that a region of the ER promoter cor-
responding to a 109 bp segment located just upstream of 
the ERF-1 site is required for transcriptional activation by 
BRCA1. This region contains two binding sites for mem-
bers of the AP2 family of transcription factors. Whether 
BRCA1′s effect is mediated through these elements, or 




MCF10A cells were obtained from the American Type 
Culture Collection (Manassas, VA). IMEC cells were 
kindly provided by Dr. James DiRenzo in the Depart-
ment of Pharmacology and Toxicology at Dartmouth 
Medical School. Cells were cultured in DMEM:Ham’s 
F-12 medium, supplemented with 100  IU/ml of penicil-
lin, 125 μg/ml of streptomycin, 2 mM l-glutamine, 10% 
fetal bovine serum, 20 ng/ml of epidermal growth factor, 
0.5 μg/ml of hydrocortisone and 8 μg/ml of insulin.
ER promoter constructs
ER promoter constructs were developed to facilitate 
localization of transcriptional control elements. They 
were generated from the previously published ER−3500-
210Luc expression plasmid kindly provided by Weigel 
[13] (Department of Surgery, Stanford University). This 
construct includes a luciferase reporter (pGL2 Basic, Pro-
mega, Madison, WI) driven by ER promoter sequence 
from −3794 to +210 nucleotides relative to the first 
nucleotide of P1 [13]. In order to include the ER-EHO 
element documented by Tang et al. [18], we incorporated 
an additional 313  bp upstream fragment. Thus, the full 
length ER promoter construct, ER−3813-210Luc, now 
P 0 P1 
a b c d e 
Fig. 1 Topology of the ER promoter. The relative positions of the transcription initiation sites P1 and P0, as well as the documented regulatory ele-
ments are illustrated. The regulatory sites are indicated as follows: (a) ER-EH0 [18], (b) a negative regulatory element [17], (c) ERBF-1 [16], (d) ERUBF-1 
[15], and (e) ERF-1 [13]
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included 4023  bp of promoter sequence, properly posi-
tioned within the pGL2 Basic luciferase reporter.
5′ Deletion constructs of ER−3813-210Luc were made 
using two approaches. The first approach used combi-
nation endonuclease digestions with NheI, located in 
the upstream subcloning site of pGL2 Basic, along with 
either AvrII, PstI, EcoRI, or NdeI. Plasmid fragment 
ends were blunted with Klenow fragment, and reactions 
were diluted out tenfold in order to favor intramolecu-
lar reactions before religation using T4 DNA ligase. The 
5′ deletion constructs created from ER−3813-210Luc in 
this manner were as follows: ER−2641-210Luc (AvrII), 
ER−1231-210Luc (PstI), ER−743-210Luc (EcoRI) and 
ER−42-210Luc (NdeI).
Because we could not find additional unique restriction 
sites within ER−42-210Luc, we used a second approach 
to produce further promoter deletion constructs. Unidi-
rectional deletions of ER−42-210Luc were made by tak-
ing advantage of the unique property of ExoIII nuclease 
to efficiently digest 5′ overhangs, while leaving 3′ over-
hangs undigested. In brief, 2.5 μg of KpnI-MluI digested 
ER−42-210Luc DNA was subjected to digestion with 
150 U of ExoIII at 15 °C. Aliquots of 3 μl (~300 ng DNA) 
were removed from the ExoIII digestion reaction at four 
time intervals (1, 20, 40, and 60  s), and placed directly 
into 16.5 μl of H2O preheated to 75 °C. Permanent inac-
tivation of ExoIII was effected by a 20  min incubation 
at 75  °C. Cleavage of the 5′ overhangs created by ExoIII 
digestion was effected by the addition of 4 U of S1 nucle-
ase and incubation at room temperature for 20 min. The 
S1 nuclease reaction was halted by the addition of 5  μl 
of STOP buffer (800  mM Tris, 20  mM EDTA, 80  mM 
MgCl2, pH 8.0). Two units of Klenow fragment and 
10 μM dNTPs were then added to blunt the 3′-overhangs, 
followed by plasmid ligation with T4 DNA ligase. Plas-
mid DNA from transformed bacteria (DH5α cells) was 
sequenced to confirm isolation of the deletion constructs 
of interest. The following promoter deletion constructs 
were generated using this method: ER−24-210Luc, ER14-
210Luc, ER62-210Luc, and ER171-210Luc. All promoter 
constructs were sequenced.
Transfections and luciferase assays
Luciferase experiments involved cotransfection of cells 
with either a BRCA1 expression plasmid or empty vec-
tor (pRK7, Genentech, S. San Francisco, CA), along 
with one of the ER promoter constructs. The BRCA1 
expression plasmid was prepared by subcloning the 
full length BRCA1 cDNA into a pRK7 backbone previ-
ously described [19]. Cotransfection of either BRCA1 
or pRK7, along with the empty pGL2 Basic vector was 
also included in each experiment. Three microliters of 
FuGENE 6 Transfection Reagent (Roche, Indianapolis, 
IN) was combined with 1.5 μg total DNA for incubation 
with adherent cells in a 9.6 cm2 plate. The ratio of lucif-
erase reporter to expression plasmid DNA was 1:4. Cells 
were 45–55% confluent at transfection and 80–90% con-
fluent at time of harvest. Cell media was changed at 24 h, 
and cells were harvested after 48 h.
Transfected cells were harvested on ice with lysis buffer 
(25 mM glycylglycine, 4 mM EGTA, 15 mM MgSO4, 1% 
Triton-X, and 0.1  mM DTT, pH 7.8), which was added 
directly to the cell culture dish following media aspira-
tion and 2 washes with cold phosphate-buffered saline 
(PBS). Dishes were subsequently scraped and lysates 
transferred to pre-chilled tubes. Cell lysates were centri-
fuged at 9000g and supernatants were stored at −80  °C 
until analysis. In a 96-well plate, 40 μl of each lysate was 
analyzed for luciferase activity in the presence of 145 μl of 
assay buffer (25 mM glycylglycine, 15 mM KPO4, 15 mM 
MgSO4, 4 mM EGTA, 25 mM ATP, and 1 mM DTT, pH 
7.8), following addition of 40 μl luciferin reagent (400 μM 
luciferin, 25 mM glycylglycine). Each lysate was also eval-
uated for protein levels, in triplicate, using the BCA Pro-
tein Assay (Pierce, Rockford, IL). Luciferase/protein for 
cells transfected with each ER promoter construct, and 
either BRCA1 or pRK7, were normalized with lysate from 
cells transfected with the empty pGL2 Basic vector.
RT‑PCR
Cell line RNA was isolated by first treating adherent cells 
with 5.7  ml of TRIzol Reagent (Invitrogen, Carlsbad, 
CA), and then scraping the solublized cell debris from a 
10  cm2 dish. TRIzol-treated cell solution was incubated 
for 15  min at room temperature, and then treated with 
1.4 ml of chloroform. After vigorous agitation, the chlo-
roform-TRIzol solution was centrifuged and the aqueous 
phase transferred to a tube containing 2.85  ml of iso-
propanol. The sample was then mixed and incubated at 
room temperature for 10  min. Following centrifugation 
the RNA pellet was washed with 70% ethanol and dried 
under vacuum. The RNA pellet was then reconstituted 
in H2O previously treated with diethyl pyrocarbonate, a 
potent inactivator of RNase.
Using 2  μg of RNA as template, each reverse tran-
scriptase (RT) reaction included 1× AMV buffer 
(Roche, Indianapolis, IN), 50  μg/ml BSA (NE Biolabs, 
Beverly, MA), 0.4  μM random hexamers (Perkin Elmer 
Corp., Foster City, CA), 200  μM each dNTP, 0.39 U/
μl RNase inhibitor (Promega, Madison, WI), and 400 U 
MMLV RT (Gibco, Gaithersburg, MD). Reactions were 
incubated at 37  °C for 2  h, followed by heat inactiva-
tion of the RT at 75  °C for 5 min. To confirm the pres-
ence of equal amounts of cDNA among the RNA 
samples, PCR amplification of human β-actin was used 
as an initial control reaction. The β-actin primers were 
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as follows: 5′-GGGACCTGACCGACTACCTC-3′ and 
5′-GGGCGATGATCTTGATCTTC-3′.
β-actin PCR reactions included 1/10 of the RT reaction 
as template, along with 1× PCR buffer (Gibco, Gaithers-
burg, MD), 2.5 mM MgCl2, 200 μM each dNTP, 125 ng 
each primer, and 1.5 U Taq Platinum. The reaction condi-
tions consisted of initial denaturation at 95 °C for 5 min, 
followed by 18 cycles of 94  °C for 30  s, 52  °C for 30  s, 
and 72  °C for 30  s. The PCR profile ended with a final 
extension phase of 72  °C for 10 min. β-actin PCR prod-
ucts were then run out on a TBE-agarose gel to confirm 
approximately equal loading of RNA templates among 
sample reactions.
ER PCR was performed with the following primers: 
5′-CTATATGTGTCCAGCCACCAACC-3′ and 5′-CTC 
TACACATTTTCCCTGGTTCCT-3′. The upper primer 
corresponded to sequence in exon 3 of ER, while the 
lower primer corresponded to sequence in exon 6 [17]. 
Therefore, these primers were specific for cDNA ampli-
fied from RNA during the RT reaction. Using 1/10 of the 
RT reaction as template, each ER PCR mixture included 
1× PCR buffer, 1.5  mM MgCl2, 200  μM each dNTP, 
0.5 μM each primer, and 1.5 U Taq Platinum. The reac-
tion conditions consisted of initial denaturation at 95 °C 
for 5 min, followed by 38 cycles of 94 °C for 1 min, 57 °C 
for 1  min, and 72  °C for 1  min. The PCR profile ended 
with a final extension phase of 72 °C for 10 min. ER PCR 
products were then run out on a TBE-agarose gel to con-
firm the presence or absence of product.
Statistical analysis
Significance of luciferase activity among BRCA1- and 
pRK7-transfected cells in Figs. 2, 3, and 4 was calculated 
using a two-tailed student t test. Normalized luciferase 
activity in BRCA1 transfections and pRK7 transfec-
tions were paired for each experiment. Among the ER 
luciferase constructs, the mean induction by BRCA1 on 
luciferase activity was analyzed for significance using an 
unpaired ANOVA analysis.
Results
To focus our examination of transactivation of the ER 
promoter by BRCA1 in a cell type relevant to its role as 
a tumor suppressor gene in breast cancer, we performed 
all experiments with two human nontumorigenic mam-
mary epithelial cell lines. The MCF10A cell line was 
used for the majority of the experiments because of its 
ease of transfection (consistently >50%), low endog-
enous level of wild type BRCA1 expression, and a wild 
type p53 status [20, 21]. In parallel, transactivation of 
the ER promoter was examined using an immortal-
ized nontumorigenic mammary epithelial cell line with 
wild type BRCA1, IMEC. IMEC cells were generated 
by introduction of a recombinant retrovirus expressing 
the catalytic subunit of human telomerase into primary 
human mammary epithelial cells [22]. Our initial experi-
ments tested the hypothesis that BRCA1 could trans-
activate the ER promoter. To test this hypothesis, we 
extended a previously described ER promoter-luciferase 
Fig. 2 Transcriptional activation of the ER promoter by BRCA1. Promoter activity for a series of ER promoter constructs with progressive 5′ deletions 
designed to sequentially remove the established regulatory sites. Fold induction in luciferase activity (x axis) is shown for each of the ER promoter 
constructs following transfection with either a BRCA1 expression plasmid (filled bars) or the empty pRK7 vector (open bars). The fold induction in 
luciferase activity is the number of photon units per unit time of data capture (RLU) divided by protein, normalized by the corresponding value from 
cells transfected with the empty pGL2 Basic vector. RLU/protein values from the empty pGL2 Basic vector ranged from ~35 to ~400, while those 
from the ER promoter constructs were >1500. Data shown represents the average of up to 7 experiments, with luciferase and protein measure-
ments performed in triplicate for each experiment
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construct, ER−3500-210Luc [13], to include 3813 nucleo-
tides upstream of P1. As shown in Fig. 1, this construct 
included all five of the documented transcriptional reg-
ulatory elements in the ER promoter region. This full 
length construct, labeled ER−3813-210Luc, was cotrans-
fected along with a BRCA1 expression plasmid, or the 
empty expression vector pRK7. Figure 2 shows the lucif-
erase activity for ER−3813-210Luc in MCF10A cells, 
demonstrating a significant augmentation (p < 0.005) in 
ER promoter transactivation when cotransfected with 
the BRCA1 expression plasmid. We observed a 50-fold 
increase over the empty luciferase vector when cotrans-
fected with BRCA1, as compared with a ninefold increase 
when cotransfected with the empty expression plasmid, 
pRK7. It is possible that the observed luciferase activity 
from the ER promoter constructs when cotransfected 
with the pRK7 plasmid was due to the effect of endog-
enous BRCA1. IMEC cells also exhibited a significant 
transactivation of the full-length promoter construct, 
with a 29.4-fold and 3.3-fold increase when co-trans-
fected with the BRCA1 and pRK7 expression plasmids, 
respectively (p < 0.0005).
Having observed transactivation of our full length ER 
promoter construct by BRCA1 in two ER-negative cell 
lines, we proceeded to test a series of deletion constructs 
designed to sequentially remove the five documented 
transcriptional regulatory sites shown in Fig.  1. These 
deletion constructs, depicted in the left-hand portion of 
Fig. 2, were cotransfected with either BRCA1 or pRK7, as 
before. The normalized luciferase values are shown in the 
right-hand portion of Fig.  2. Although there was some 
variation in the magnitude of induction of luciferase 
activity by BRCA1, when compared with the induction 
seen with the empty pRK7 plasmid there were no signifi-
cant differences between the constructs (p > 0.9 for both 
MCF10A and IMEC cells). These data suggested that the 
segment of the ER promoter which mediates transactiva-
tion by BRCA1 was contained within the region extend-
ing from 42 bp upstream to 210 bp downstream of the P1 
transcriptional start site.
In order to localize more precisely the segment of 
promoter sequence in proximity to P1 responsible for 
BRCA1 transactivation, we prepared additional dele-
tion constructs by limited ExoIII nuclease digestion of 
the ER−42-210Luc construct. These constructs and their 
promoter activity following cotransfection with either 
BRCA1 or pRK7 in MCF10A cells are shown in Fig.  3. 
Induction of promoter activity by BRCA1 was not sig-
nificantly diminished by removal of up to 103 nucleo-
tides from the 5′ end of the ER−42-210Luc construct 
(p  >  0.8 for the series ER−42-210Luc, ER−24-210Luc, 
ER14-210Luc, and ER62-201Luc). However, as indicated 
in Fig. 3, the ER171-210Luc construct did not show any 
induction of luciferase activity upon transfection with 
either BRCA1 or pRK7. The fold inductions obtained 
with co-transfection of the BRCA1 expression plas-
mid for the entire ER promoter deletion series in both 
MCF10A and IMEC cells is illustrated in Fig.  4. These 
data clearly indicate that the specific region of the ER 
promoter mediating transactivation by BRCA1 is located 
between 62 and 171 bp downstream of the P1 transcrip-
tional start site.
Fig. 3 Transcriptional activation by BRCA1 with a series of ExoIII-generated ER promoter luciferase constructs. Luciferase activity for ExoIII-generated 
ER promoter constructs in MCF10A cells. Fold induction in luciferase activity (x axis) is shown for ER promoter constructs following co-transfection 
with either a BRCA1 expression plasmid (filled bars) or the empty pRK7 vector (open bars). Fold induction values were calculated as in Fig. 2. Data 
shown represents the average of 2–7 experiments, with luciferase and protein measurements performed in triplicate for each experiment
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To determine if the induction of ER promoter activ-
ity by BRCA1 was seen at the level of the endogenous 
gene (i.e. at the mRNA level), we performed RT-PCR 
on extracts isolated following transfection with BRCA1 
or pRK7. Figure  5 indicates that ER mRNA is barely 
detectable in pRK7-transfected mRNA, as would be 
expected in ER-negative cell lines. Following transfection 
with BRCA1, MCF10A cells showed an increased level 
of ER mRNA, suggesting that the endogenous ER pro-
moter was transactivated. Preparation of mRNA from an 
Fig. 4 Localization of the segment of ER promoter mediating transactivation by BRCA1. Mean fold induction in luciferase activity (y axis) by BRCA1 
in MCF10A cells (top panel) and IMEC cells (bottom panel) is indicated for all ER promoter constructs (x axis), calculated as the ratio of promoter activ-
ity when co-transfected with BRCA1, divided by promoter activity measured with co-transfection of pRK7. Standard error of the mean is indicated
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untransfected ER-positive cell line, MCF7, was used as a 
control. Figure 5 illustrates that although BRCA1 induces 
the production of ER mRNA in MCF10A cells, the lev-
els are still much lower than in an ER-positive cell line. 
Induction of ER mRNA by BRCA1 was not detectable 
in IMEC cells (not shown). This was contrary to expec-
tation considering that our previous luciferase results 
showed BRCA1 could transactivate ER promoter activity 
in both MCF10A and IMEC cells, and may be a function 
of epigenetic silencing of the endogenous ER promoter in 
IMEC cells.
Discussion
Investigators have reported that ER transcriptional regu-
lation is at least in part influenced by the activity of cer-
tain cis- and trans-acting factors in breast cancer cell 
lines [13–18]. Inherited primary breast cancers that are 
characterized by a mutation in the tumor suppressor 
gene, BRCA1, do not express ER in two-thirds to 90% 
of patients [1–3]. Therefore, we wanted to determine if 
ectopic levels of BRCA1 could influence the activity of 
the ER promoter, potentially through the regulation of 
these transcriptional sites. The data indicated that in fact 
BRCA1 could transactivate an ER promoter-containing 
construct driving luciferase expression in two nontumo-
rigenic, ER-negative, cell lines.
The 109  bp portion of P1 found to mediate BRCA1 
transactivation of ER did not correspond to any of the 
documented transcriptional sites in the ER gene. This 
109 bp segment was located just upstream of the ERF-1 
site first described by DeConinck et al. [13], and included 
a nearby site homologous to ERF-1 previously shown to 
bind with less affinity to AP2γ. This homologous ERF-1 
site is located between positions 130 and 149. Follow-
ing a search of a transcription factor data base (Transfac: 
Transcription Factor Database, http://transfac.gbf.de/
TRANSFAC/) with the sequence of the 109 bp P1 region 
transactivated by BRCA1, we noted an additional AP2 
site present at position 64–75. Not identified were any 
of the DNA-binding sequences for BRCA1 reported by 
Cable et  al. [23], or an Oct-1 binding site implicated by 
Hosey et al. [24] as important to BRCA1’s impact on ER 
expression.
Induction of the ER endogenous gene by BRCA1 was 
evident in MCF10A cells, as shown in Fig. 5. This obser-
vation is consistent with the report of Hosey et  al. [24] 
that expression of wild type BRCA1 in a BRCA1-mutated 
and ER-negative breast cancer cell line (HCC1937) 
resulted in detectable ER mRNA levels. Of note, transient 
transfection of BRCA1 in MCF10A cells was not suffi-
cient to induce ER mRNA to the level of an ER-positive 
cell line.
Conclusion
The role of BRCA1 in the transcriptional regulation of ER 
is a critical question in breast cancer research, with impli-
cations for both prevention and treatment. The work pre-
sented here demonstrates the importance of a CpG-rich 
109 bp segment in the transactivation of the ER promoter 
by BRCA1 in two transformed non-tumorigenic human 
mammary epithelial cell lines. Our observations with 
IMEC cells suggest that methylation within this region 
may constitute an important mechanism of epigenetic 
control that affects the ability of BRCA1 to induce the 
endogeneous ER gene’s promoter activity. If true, we 
would predict that the addition of a demethylating agent 
such as azacytidine would allow for detectable activation 
of the endogenous gene by BRCA1. A notable limitation 
to this work is that transformed cell lines with wild type 
BRCA1 were studied, and not primary cells or BRCA1-
null cell lines. Use of cells completely lacking endogenous 
BRCA1 would facilitate experiments correlating this 
effect of BRCA1 with its disease-causing mutations, thus 
linking our observations with critical aspects of patho-
genesis of breast cancer in BRCA1 mutation carriers.
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